Chirurgische Therapie und Evaluation von Prognosefaktoren bei Wirbelsäulenmetastasen durch Nieren-Zell-Karzinome

Ulmar, Benjamin; Catalkaya, Sibel; Naumann, Ulrike; Gerstner, Susanne; Çakır, Burcu; Schmidt, R; Reichel, Heiko; Huch, Klaus

doi:10.1055/s-2006-921465

Cited by 13 publications

(4 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Patients with osseous metastases of RCC have an unfavorable prognosis. In some studies, more than 50% of patients die within the first year [7,9,10,17,18]. The survival rate for our patients was with 58.4% at 1 year and 11.9% at 5 years slightly better.…”

Section: Discussionsupporting

confidence: 43%

Bone metastases from renal cell carcinoma: patient survival after surgical treatment

Fottner

Szalantzy

Wirthmann

et al. 2010

BMC Musculoskelet Disord

113

View full text Add to dashboard Cite

BackgroundSurgery is the primary treatment of skeletal metastases from renal cell carcinoma, because radiation and chemotherapy frequently are not effecting the survival. We therefore explored factors potentially affecting the survival of patients after surgical treatment.MethodsWe retrospectively reviewed 101 patients operatively treated for skeletal metastases of renal cell carcinoma between 1980 and 2005. Overall survival was calculated using the Kaplan-Meier method. The effects of different variables were evaluated using a log-rank test.Results27 patients had a solitary bone metastasis, 20 patients multiple bone metastases and 54 patients had concomitant visceral metastases. The overall survival was 58% at 1 year, 37% at 2 years and 12% at 5 years. Patients with solitary bone metastases had a better survival (p < 0.001) compared to patients with multiple metastases. Age younger than 65 years (p = 0.036), absence of pathologic fractures (p < 0.001) and tumor-free resection margins (p = 0.028) predicted higher survival. Gender, location of metastases, time between diagnosis of renal cell carcinoma and treatment of metastatic disease, incidence of local recurrence, radiation and chemotherapy did not influence survival.ConclusionsThe data suggest that patients with a solitary metastasis or a limited number of resectable metastases are candidates for wide resections. As radiation and chemotherapy are ineffective in most patients, surgery is a better option to achieve local tumor control and increase the survival.

show abstract

Section: Discussionsupporting

confidence: 43%

Bone metastases from renal cell carcinoma: patient survival after surgical treatment

Fottner

Szalantzy

Wirthmann

et al. 2010

BMC Musculoskelet Disord

113

View full text Add to dashboard Cite

show abstract

“…After lungs and liver, skeletal system and bones bear the brunt of systemic metastases (Macedo et al 2017 ; Maccauro et al 2011 ). Surgical options for managing spinal metastases encompass a spectrum, from biopsy coupled with vertebroplasty or kyphoplasty (Stangenberg et al 2017 ; Georgy 2010 ), to spinal canal decompression in isolation (Patchell et al 2005 ), or in conjunction with minimally invasive percutaneous procedures (Miscusi et al 2015 ) and open instrumentation with augmented screws (Ringel et al 2017 ; Park et al 2019a ), at times necessitating anterior–posterior stabilization (Ulmar et al 2006 ; Gezercan et al 2016 ). The overarching objective of surgical intervention is the mitigation or prevention of neurological deficits, coupled with a focus on enhancing the patient’s quality of life (Fehlings et al 2016 ; Depreitere et al 2020 ).…”

Section: Introductionmentioning

confidence: 99%

Synchronous versus metachronous spinal metastasis: a comparative study of survival outcomes following neurosurgical treatment

Banat,

Potthoff,

Hamed

et al. 2024

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

Purpose Patients with spinal metastases (SM) from solid neoplasms typically exhibit progression to an advanced cancer stage. Such metastases can either develop concurrently with an existing cancer diagnosis (termed metachronous SM) or emerge as the initial indication of an undiagnosed malignancy (referred to as synchronous SM). The present study investigates the prognostic implications of synchronous compared to metachronous SM following surgical resection. Methods From 2015 to 2020, a total of 211 individuals underwent surgical intervention for SM at our neuro-oncology facility. We conducted a survival analysis starting from the date of the neurosurgical procedure, comparing those diagnosed with synchronous SM against those with metachronous SM. Results The predominant primary tumor types included lung cancer (23%), prostate cancer (21%), and breast cancer (11.3%). Of the participants, 97 (46%) had synchronous SM, while 114 (54%) had metachronous SM. The median overall survival post-surgery for those with synchronous SM was 13.5 months (95% confidence interval (CI) 6.1–15.8) compared to 13 months (95% CI 7.7–14.2) for those with metachronous SM (p = 0.74). Conclusions Our findings suggest that the timing of SM diagnosis (synchronous versus metachronous) does not significantly affect survival outcomes following neurosurgical treatment for SM. These results support the consideration of neurosurgical procedures regardless of the temporal pattern of SM manifestation.

show abstract

“…Skeletal metastases occur in more than 50% of malignant tumors and up to 70% of breast cancer patients ( 5 , 6 ). Patients with renal cell carcinoma (RCC) and SM demonstrated unfavorable prognosis in which more than 50% of patients die within the first year of diagnosis of SM ( 7 – 10 ). The detection of SM might affect cancer staging and follow-up, as it can affect the treatment plan.…”

Section: Introductionmentioning

confidence: 99%

Skeletal Metastasis as Detected by 18F-FDG PET with Negative CT of the PET/CT: Frequency and Impact on Cancer Staging and/or Management

et al. 2016

View full text Add to dashboard Cite

ObjectivesThe aim of our study is to assess the frequency of detection of PET-positive computed tomography (CT)-negative skeletal metastases (SM) and determine the impact of such detection on staging and/or management in patients who had FDG PET/CT as part of the cancer work-up.MethodsWe retrospectively reviewed 2000 18F-FDG PET/CT scans of known cancer patients. A log was kept to record cases of suspected SM with or without bone changes from the low-dose non-contrast CT. The presence or absence of SM was evaluated based on available pathological and clinical data. The impact of detection of such lesions on cancer staging and/or management was evaluated by a board certified oncologist.ResultsOf the 2000 cases, 18F-FDG PET/CT suggested SM in 146/2000 (7.3%). Of those 146 cases, 105 (72%) were positive on both PET and CT. The remaining 41 (28%) had PET-positive CT-negative bone lesions. SM was confirmed in 36/41 (88%) PET-positive/CT-negative cases. This was based on biopsy, imaging, or clinical follow-up. The detection of PET-positive CT-negative SM did not change staging or management in 7/36 (19.4%). However, staging and/or management was affected in 29/36 (80.6%).ConclusionSM is not uncommon in 18F-FDG PET/CT, as it accounts for 146/2000 (7.3%) of cases. PET demonstrated FDG-avid SM without a CT abnormality in at least 36/146 (25%). Patients staging and/or management changed in 29/36 (80.5%). We concluded that 18F-FDG PET is sensitive in the detection of SM with significant impact on staging and/or management.

show abstract

Chirurgische Therapie und Evaluation von Prognosefaktoren bei Wirbelsäulenmetastasen durch Nieren-Zell-Karzinome

Cited by 13 publications

References 8 publications

Bone metastases from renal cell carcinoma: patient survival after surgical treatment

Bone metastases from renal cell carcinoma: patient survival after surgical treatment

Synchronous versus metachronous spinal metastasis: a comparative study of survival outcomes following neurosurgical treatment

Skeletal Metastasis as Detected by 18F-FDG PET with Negative CT of the PET/CT: Frequency and Impact on Cancer Staging and/or Management

Contact Info

Product

Resources

About